Cargando…

Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants have seriously attacked the antibody barrier established by natural infection and/or vaccination, especially the recently emerged BQ.1.1 and XBB.1. However, crucial mechanisms underlying the virus escape and the broad n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ju, Bin, Fan, Qing, Liu, Congcong, Shen, Senlin, Wang, Miao, Guo, Huimin, Zhou, Bing, Ge, Xiangyang, Zhang, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201307/ https://www.ncbi.nlm.nih.gov/pubmed/37219999 http://dx.doi.org/10.1016/j.celrep.2023.112532

Ejemplares similares

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1
por: Miller, Jessica, et al.
Publicado: (2023)

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
por: Shah, Masaud, et al.
Publicado: (2023)

Striking antibody evasion of SARS-CoV-2 Omicron sub-lineages BQ.1.1, XBB.1 and CH.1.1
por: Ju, Bin, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7
por: Zhang, Yanfang, et al.
Publicado: (2023)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants
por: Popovic, Marko
Publicado: (2023)

Poor neutralizing antibody responses against SARS‐CoV‐2 Omicron BQ.1.1 and XBB in Norway in October 2022
por: Vikse, Elisabeth Lea, et al.
Publicado: (2023)

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
por: Ehmsen, Sidse, et al.
Publicado: (2023)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
por: Zhu, Airu, et al.
Publicado: (2023)

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
por: Carr, Edward J, et al.
Publicado: (2023)

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
por: Amano, Masayuki, et al.
Publicado: (2023)

A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB
por: Ding, Yuan, et al.
Publicado: (2023)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
por: Pochtovyi, Andrei A., et al.
Publicado: (2023)

Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
por: Mykytyn, Anna Z, et al.
Publicado: (2023)

An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB
por: He, Qingwen, et al.
Publicado: (2023)

Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
por: Davis-Gardner, Meredith E., et al.
Publicado: (2022)

Adaptability of single nucleotide polymorphism (SNP)-PCR for subtyping SARS-CoV-2 and a new SNP-PCR for XBB, XBB.1.5, and B.Q.1/B.Q.1.1
por: Ritchie, Gordon, et al.
Publicado: (2023)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
por: Ao, Danyi, et al.
Publicado: (2023)

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants
por: Faraone, Julia N., et al.
Publicado: (2023)

Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2022)

Neutralization of Omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273
por: Hernández, Jesús, et al.
Publicado: (2023)

Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients
por: Bruel, Timothée, et al.
Publicado: (2023)

Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5
por: Entzminger, Kevin C, et al.
Publicado: (2023)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?
por: Varghese, Ryan, et al.
Publicado: (2023)

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
por: Zuo, Fanglei, et al.
Publicado: (2023)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations
por: Hyun, Hak-Jun, et al.
Publicado: (2023)

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China
por: Wang, Xun, et al.
Publicado: (2023)

Emergence BQ.1 and BQ.1.1 as newly identified omicron subvariants: current scenario and future outlook – an update
por: Akash, Shopnil, et al.
Publicado: (2023)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tga061m42v657bs575dovao13c